Login to Your Account

Vion Stops Triapine Single Agent Study, Focuses On Combination

By Karen Pihl-Carey

Monday, February 9, 2004
Vion Pharmaceuticals Inc. discontinued enrollment of a Phase II study of Triapine as a single agent in patients with prostate cancer in order to focus its resources on the drug's more promising trials - those studying it as a combination therapy. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription